Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction

A. Afşin Oktay, Sanjiv J. Shah*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations

Abstract

Hypertension is a major contributor to the development of heart failure with preserved ejection fraction (HFpEF). Our understanding of the epidemiology and pathophysiology of HFpEF in relation to hypertension has increased considerably in recent years. We now know that the pathophysiologic relationship between hypertension and HFpEF is more complex than simply the development of left ventricular hypertrophy and diastolic dysfunction and that there are multiple ways in which hypertension interacts with other comorbidities, the vasculature, and the heart to predispose to HFpEF. Although the treatment of HFpEF has been challenging, there is widespread agreement that control of systemic blood pressure is important in the management of these patients. Here we review the relationship between hypertension and HFpEF, focusing on (1) epidemiology and (2) pathophysiology of HFpEF in relation to hypertension; (3) prevention of HFpEF by controlling hypertension; and (4) established and novel therapeutics for hypertension in the setting of HFpEF.

Original languageEnglish (US)
Article number545
JournalCurrent Cardiology Reports
Volume16
Issue number12
DOIs
StatePublished - Dec 2014

Keywords

  • Diastolic heart failure
  • Epidemiology
  • Hypertension
  • Pathophysiology
  • Pharmacology

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Current Perspectives on Systemic Hypertension in Heart Failure with Preserved Ejection Fraction'. Together they form a unique fingerprint.

Cite this